

References

Chapter 24

- 1 Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. *New England Journal of Medicine*. 2003;**349**:1157–67.
- 2 European Medicines Agency. 2001. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003459.pdf (last accessed 18 November 2015).
- 3 Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet*. 2012;**379**(9832):2151–61.
- 4 Shirkey H. Therapeutic orphans. *Journal of Pediatrics*. 1968;**72**(1):119–20.
- 5 Shirkey HC. Therapeutic orphans – everybody’s business. *Annals of Pharmacotherapy*. 2006;**40**(6):1174.
- 6 European Commission. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf (last accessed 18 November 2015).
- 7 Food and Drug Administration Safety and Innovation Act (FDASIA). Available from: <http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentsToTheFDCAAct/FDASIA/ucm20027187.htm> (last accessed 18 November 2015).
- 8 Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Nicolosi A, Giaquinto C, et al. Databases for pediatric medicine research in Europe – assessment and critical appraisal. *Pharmacoepidemiology & Drug Safety*. 2008;**17**(12):1155–67.
- 9 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2013. Available from: http://www.whocc.no/filearchive/publications/1_2013guidelines.pdf (last accessed 18 November 2015).
- 10 Liem TBY, Heerdink ER, Egberts ACG, Rade-maker CMA. Quantifying antibiotic use in paediatrics: a proposal for neonatal DDDs. *European Journal of Clinical Microbiology and Infectious Disease*. 2010;**29**(10):1301–3.
- 11 Valcourt K, Norozian F, Lee H, Raszynski A, Torbati D, Totapally BR. Drug use density in critically ill children and newborns: analysis of various methodologies. *Pediatric Critical Care Medicine*. 2009;**10**(4):495–9.
- 12 Sequi M, Campi R, Clavenna A, Bonati M. Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies. *European Journal of Clinical Pharmacology*. 2013;**69**(3):599–604.
- 13 Kimland E, Odland V. Off-label drug use in pediatric patients. *Clinical Pharmacology and Therapeutics*. 2012;**91**(5):796–801.
- 14 Pandolfini C, Kaguelidou F, Sequi M, Jacqz-Aigrain E, Choonara I, Turner MA, et al. Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. *European Journal of Clinical Pharmacology*. 2013;**69**(4):1031–6.
- 15 Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, et al. Medicines for children licensed by the European Medicines Agency (EMA): the balance after 10 years. *European Journal of Clinical Pharmacology*. 2006;**62**(11):947–52.

- 16 Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowicz M, Clark RH, et al. Drug labeling and exposure in neonates. *Journal of the American Medical Association Pediatrics*. 2014;**168**(2):130–6.
- 17 American Academy of Pediatrics. Off-label use of drugs in children. *Pediatrics*. 2014;**133**(3): 563–7.
- 18 Pandolfini C, Bonati M. A literature review on off-label drug use in children. *European Journal of Paediatrics*. 2005;**164**(9):552–8.
- 19 Food and Drug Administration. ‘Off-Label’ and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices – Information Sheet. Available from: <http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm> (last accessed 18 November 2015).
- 20 Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, et al. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. *Pharmacology Research*. 2008;**58**(5–6):316–22.
- 21 Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. *European Journal of Clinical Pharmacology*. 2012;**68**(1):21–8.
- 22 Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. *BMC Medicine*. 2013;**11**:238.
- 23 Haslund-Krog S, Mathiasen R, Christensen HR, Holst H. The impact of legislation on drug substances used off-label in paediatric wards—a nationwide study. *European Journal of Clinical Pharmacology*. 2014;**70**(4):445–52.
- 24 Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. *Drug Safety*. 2004;**27**(13):1059–67.
- 25 Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a population-based study in Germany. *BMC Public Health*. 2013;**13**(1):631.
- 26 Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, et al. Drug use in children: cohort study in three European countries. *British Medical Journal*. 2008;**337**:a2245.
- 27 Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, et al. The prescribing of analgesics and non-steroidal anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. *Pharmacology Research*. 2010;**62**(3):243–8.
- 28 Sen EF, Verhamme KM, Neubert A, Hsia Y, Murray M, Felisi M, et al. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. *European Journal of Paediatrics*. 2011;**170**(1):81–92.
- 29 Hsia Y, Neubert A, Sturkenboom MC, Murray ML, Verhamme KM, Sen F, et al. Comparison of anti-epileptic drug prescribing in children in three European countries. *Epilepsia*. 2010;**51**(5):789–96.
- 30 Weinstein SJ, House SA, Chang CH, Wasserman JR, Goodman DC, Morden NE. Small geographic area variations in prescription drug use. *Pediatrics*. 2014;**134**(3):563–70.
- 31 Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. *Pediatrics*. 2012;**130**(1):23–31.
- 32 Olsson J, Kimland E, Pettersson S, Od Lind V. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient care – a nationwide study. *Acta Paediatrica*. 2011;**100**(9):1272–5.
- 33 Feudtner C, Dai D, Faerber J, Metjian TA, Luan X. Pragmatic estimates of the proportion of pediatric inpatients exposed to specific medications in the USA. *Pharmacoepidemiology & Drug Safety*. 2013;**22**(8):890–8.
- 34 Kimland E, Nydert P, Od Lind V, Böttiger Y, Lindemalm S. Paediatric drug use with focus on off-label prescriptions at Swedish hospitals – a nationwide study. *Acta Paediatrica*. 2012;**101**(7):772–8.
- 35 Lass J, Käär R, Jõgi K, Varendi H, Metsvaht T, Lutsar I. Drug utilisation pattern and off-label use of medicines in Estonian neonatal units. *European Journal of Clinical Pharmacology*. 2011;**67**(12):1263–71.
- 36 Santos DB, Clavenna A, Bonati M, Coelho HL. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil. *European Journal of Clinical Pharmacology*. 2008;**64**(11):1111–18.
- 37 Flores-Pérez C, Flores-Pérez J, Juárez-Olguín H, Barranco-Garduño LM. Frequency of drug consumption and lack of pediatric formulations. *Acta Pediátrica de México*. 2008;**29**(1):16–20.
- 38 Shankar PR, Upadhyay DK, Subish P, Dubey AK, Mishra P. Prescribing patterns among paediatric

- inpatients in a teaching hospital in western Nepal. *Singapore Medical Journal*. 2006;**47**(4):261–5.
- 39 Chirdkiatgumchai V, Xiao H, Fredstrom BK, Adams RE, Epstein JN, Shah SS, Brinkman WB, Kahn RS, Froehlich TE. National trends in psychotropic medication use in young children: 1994–2009. *Pediatrics*. 2013;**132**(4):615–23.
- 40 Karanges EA, Stephenson CP, McGregor IS. Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: focus on children, adolescents and prescriber specialty. *Australian and New Zealand Journal of Psychiatry*. 2014;**48**(10):917–31.
- 41 Walkup, J (The Work Group on Quality Issues). Practice parameter on the use of psychotropic medication in children and adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry*. 2009;**48**(9):961–73.
- 42 Faber A, de Jong-van den Berg LT, van den Berg PB, Tobi H. Psychotropic co-medication among stimulant-treated children in The Netherlands. *Journal of Child and Adolescent Psychopharmacology*. 2005;**15**(1):38–43.
- 43 Clavenna A, Rossi E, Derosa M, Bonati M. Use of psychotropic medications in Italian children and adolescents. *European Journal of Paediatrics*. 2007;**166**(4):339–47.
- 44 Clavenna A, Bonati M, Rossi E, De RM. Increase in non-evidence based use of antidepressants in children is cause for concern. *British Medical Journal*. 2004;**328**(7441):711–12.
- 45 Clavenna A, Bonati M. Differences in antibiotic prescribing in paediatric outpatients. *Archives of Disease in Childhood*. 2011;**96**(6):590–5.
- 46 Holstiege J, Schink T, Molokhia M, Mazzaglia G, Innocenti F, Oteri A, et al. Systemic antibiotic prescribing to paediatric outpatients in 5 European countries: a population-based cohort study. *BMC Pediatrics*. 2014;**14**:174.
- 47 Vaz LE, Kleinman KP, Raebel MA, Nordin JD, Lakoma MD, Dutta-Linn MM, Finkelstein JA. Recent trends in outpatient antibiotic use in children. *Pediatrics*. 2014;**133**(3):375–85.
- 48 Rashed AN, Wong IC, Wilton L, Tomlin S, Neubert A. Drug Utilisation Patterns in Children Admitted to a Paediatric General Medical Ward in Five Countries. *Drugs Real World Outcomes*. 2015;**2**(4):397–410.
- 49 Amadeo B, Zarb P, Muller A, Drapier N, Vankerckhoven V, Rogues AM, et al.; ESAC III Hospital Care Subproject Group. European Surveillance of Antibiotic Consumption (ESAC) point prevalence survey 2008: paediatric antimicrobial prescribing in 32 hospitals of 21 European countries. *Journal of Antimicrobial Chemotherapy*. 2010;**65**(10):2247–52.
- 50 Versporten A, Sharland M, Bielicki J, Drapier N, Vankerckhoven V, Goossens H; ARPEC Project Group Members. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. *Pediatric Infectious Disease Journal*. 2013;**32**(6):e242–53.